Investment news

Samsung Biologics (KRX: 207940.KS) announced that it has reached an agreement with Biogen for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis’ growth outlook.

Unilever Plc plans to sharpen its focus on health and hygiene and sell off slow-growth brands as it weighs making a higher offer for GlaxoSmithKline Plc’s consumer unit.

Novartis announced that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.

Sanofi announced today that it has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform, Pro-XTEN, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.

Organon (NYSE: OGN), and Forendo Pharma announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health.

Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines

The Bill & Melinda Gates Foundation would make a $35 million equity investment in privately owned Exscientia Ltd to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Wednesday.

Takeover could value medical-equipment maker Hill-Rom at around $150 a share